FDA Reverses Huntington's Gene Therapy Stance; RFK Jr.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA reversed its opposition to a closely watched gene therapy for Huntington's disease, clearing a path for biotech company UniQure to file for U.S. approval.
- Lauren Holder, a Huntington's disease advocate living with the early stages of the disease, joins the episode to discuss what the FDA reversal means for the patient community.
- Robert F. Kennedy Jr. earned his role as HHS Secretary through a pledge to "Make America Healthy Again," entering with a long to-do list and a stated goal of delivering measurable improvements within two years.
- Isabella Cueto, STAT's chronic disease reporter, has been closely tracking Kennedy and the MAHA movement's actions and joins to take stock of his performance.
Why it matters: The FDA reversal directly benefits the Huntington's patient community and clears UniQure to pursue U.S. market entry, while the two-year mark on Kennedy's HHS tenure offers a concrete checkpoint for measuring whether his MAHA agenda has produced tangible health improvements.
